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Platelet lifespan is regulated by intrinsic apoptosis. Platelet apoptosis can be triggered by BH3 
mimetics that inhibit the pro-survival Bcl-2 family protein, Bcl-xL. Here, we investigated several small 
molecules that are reported to act as BH3 mimetics and compared their effects to the well-
established BH3 mimetic, ABT-737. Platelet phosphatidylserine (PS) exposure was determined by 
flow cytometry. Changes in cytosolic Ca2+ signalling were detected using Cal-520. Plasma membrane 
integrity was determined by calcein leakage. The roles of caspases and calpain in these processes 
were determined using Q-VD-OPh and calpeptin, respectively. As previously reported, ABT-737 
triggered PS exposure in a caspase-dependent manner and calcein loss in a caspase and calpain-
dependent manner. In contrast, AT-101 and sabutoclax triggered PS exposure independently of 
caspases. HA14-1 also triggered PS exposure in a caspase-independent but calpain-dependent 
manner. There were also significant differences in the pattern and protease-dependency of cytosolic 
Ca2+ signalling in response to these drugs compared to ABT-737. Since there are clear differences 
between the action of ABT-737 and the other putative BH3 mimetics investigated here, AT-101, 
HA14-1 and sabutoclax cannot be considered as acting as BH3 mimetics in platelets. Furthermore, 
the platelet death caused by these drugs is likely to be distinct from apoptosis. 
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Platelet lifespan is regulated by the intrinsic apoptotic pathway. Platelet apoptosis can be triggered 
by BH3 mimetics that inhibit the pro-survival Bcl-2 family protein, Bcl-xL.1,2 Such BH3 mimetics have 
become useful tools to understand the mechanisms that regulate platelet apoptosis. ABT-737, the 
BH3 mimetic most well-characterised in platelets, inhibits Bcl-2 and Bcl-xL, triggering caspase 
activation, phosphatidylserine (PS) exposure in a Bak/Bax-dependent manner,3 followed by release 
of PS-exposing extracellular vesicles (EVs) and secondary necrosis in vitro. 4 The orally available 
analogue, ABT-263 (navitoclax), also triggers platelet apoptosis and is associated with dose-limiting 
thrombocytopenia.5 In contrast, ABT-199 (venetoclax), which is more selective for Bcl-2 over Bcl-xL, 
spares platelets and has been approved for treatment of chronic lymphocytic leukaemia.6,7 It is 
therefore important to understand which drugs trigger apoptosis in platelets.  
In this study, we investigated several small molecules that are reported to act as BH3 mimetics. AT-
101, the (-) enantiomer of gossypol, inhibits Mcl-1, Bcl-2 and Bcl-xL,8 and induced caspase-
dependent apoptosis in various cancer cell lines both in vivo and in vitro. 9,10 The pan-Bcl-2 family 
inhibitor, sabutoclax (BI-97C1), is also structurally related to gossypol and suppressed tumour cell 
growth via activation of BAK and BAX both in vivo and in vitro.11 TW-37 is a relatively more selective 
inhibitor of Bcl-2 derived by structure-based design from AT-101.8 TW-37 inhibited proliferation of 
lymphoma cells without significant effect on normal peripheral blood lymphocytes.12 HA14-1, a 
ligand of a Bcl-2 surface pocket, showed cytotoxic effects in vitro and in vivo, either alone or in 
combination with cytotoxic therapy. 13–15  
We compared their effects on human platelets in vitro to those caused by ABT-737.  However, 
although we found that some trigger platelet death, the mechanism and pharmacology of platelet 




Washed platelet preparation 
Blood was drawn by venepuncture into sodium citrate (3.2% v/v) from healthy, drug-free volunteers, 
who had given written, informed consent in accordance with the Declaration of Helsinki. Use of 
human blood for these experiments was approved by the Human Biology Research Ethics 
Committee, University of Cambridge. Washed platelets were prepared at 5 x 107 platelets/ml as 
previously described.16 Where required, platelets were incubated for 10 minutes with calcein-
acetoxymethyl (AM) ester (1 μM; 10 min) or Cal-520-AM (500 nM; 10 min). Platelets were rested (30 
°C, 30 minutes) prior to stimulation with pro-apoptotic drugs. CaCl2 (2 mM) was added immediately 
prior to stimulation. 
 
Flow Cytometry 
Following stimulation, samples were stained with fluorescein isothiocyanate (FITC)-conjugated 
annexin V (AnV) (eBioscience), to detect exposed PS (FL1), unless otherwise indicated, and PE-Cy7-
conjugated anti-CD41 antibody (eBioscience), to distinguish platelet-derived events. Samples were 
analysed using a BD Accuri C6 flow cytometer. PE-Cy7 fluorescence (FL3) was used to trigger event 
acquisition. PS-positive platelet-derived EVs were defined as CD41+/AnV-positive (AnV+) events that 
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were smaller than 1 μm. The 1 μm gate was set in forward scatter using 1 μm silica beads.16 To 
monitor mitochondrial membrane potential, washed platelets (5 x 107/ml) were incubated with 
trimetylrhodamine methyl ester (TMRM; 500 nM, 30 °C, 30 min; ThermoFisher, U.K.) prior to 
treatment as indicated in the main text. TMRM fluorescence was acquired on FL2. 
 
Measurement of cytosolic Ca2+ concentration ([Ca2+]cyt) 
Cal-520-loaded platelets were stimulated in black-walled microplates at 30 °C. Fluorescence 
(excitation: 485 nm; emission: 520 nm) was recorded using a FLUOStar OMEGA (BMG LabTech). 
 
Sources of materials 
Reagents were from Sigma (Poole, Dorset, U.K.) unless otherwise stated. ABT-263, ABT-737, ABT-
199, AT-101, HA14-1, sabutoclax and TW-37 were from Selleck Chemicals (Stratech Scientific, Ely, 
U.K.). Cal-520 acetoxymethyl (AM) ester was from ATT Bioquest (Sunnyvale, CA, U.S.A.). Calcein AM 




Data are reported as mean ± standard error of mean (SEM) from at least 5 independent experiments 
and compared by one-way ANOVA in GraphPad Prism. 
 
Results  
Comparison of the effects of putative BH3 mimetics on PS exposure and release of PS-exposing EVs 
To compare the effects of commercially-available BH3 mimetics, platelets were treated with ABT-
737, ABT-263, ABT-199, HA14-1, TW-37, AT-101, and sabutoclax (0.1, 1, 10 µM) for 3 hours. This late 
timepoint was chosen as the BH3 mimetic most well-characterised in platelets, ABT-737, requires 
several hours of treatment to see the largest effects.1–4,17 Platelet PS exposure was detected using 
annexin V (AnV) and procoagulant extracellular vesicles (EVs) were detected as CD41+, AnV+ events 
less than 1 µm, as previously described.16  
ABT-737 increased the percentage of AnV+ platelets in a concentration-dependent manner, which 
was accompanied by release of AnV+ EVs (Fig. 1), as previously reported.4 ABT-263 had a similar 
effect but was less potent. ABT-199 did not increase AnV binding up to 10 M under these 
conditions, consistent with ABT-737 and ABT-263 inhibiting Bcl-xL and Bcl-2, but ABT-199 being 
selective for Bcl-2.6 HA14-1, AT-101 and sabutoclax all triggered platelet AnV binding and AnV+ EV 
release at 10 µM. TW-37 had a very weak effect, with only 5.0 ± 0.9 % AnV+ platelets at 10 µM. This 
may reflect its low affinity to Bcl-xL, reported as 1.1 µM to recombinant Bcl-xL in vitro.8  
ABT-737-induced AnV binding occurred slowly. Under our conditions, very few platelets AnV+ at 60 
minutes following stimulation and 37.9 ± 6.0 % platelets AnV+ by 90 minutes (Fgi. 2A). ABT-263 
induced AnV binding with a similar timecourse. In contrast, HA14-1-induced AnV binding was more 
rapid, with 61.6 ± 4.4 % platelets AnV+ after 60 minutes. AT-101-induced AnV binding showed a 
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different pattern, with 22.1 ± 5.9 % AnV+ platelets within 10 minutes. This level remained constant 
until 90 minutes, when it began to increase further. The effect of sabutoclax was less consistent, a 
feature that we found repeatably. The extent of AnV binding in response to sabutoclax varied in the 
5 independent experiments (from 27.5 – 82.0 % at 3 hours). The timecourse was similarly variable.  
To investigate the effect of these putative BH3 mimetics on mitochondrial membrane potential, 
platelets were loaded with TMRM. This reflects late damage to the mitochondria rather than early 
release of cytochrome c.4,18  The timecourse of loss of TMRM fluorescence matched that AnV 
binding. ABT-737 and ABT-263 led to a reduction in the percentage of TMRM-positive platelets. As 
with AnV binding, this was relatively slow. HA14-1-induced loss of TMRM fluorescence started 
earlier, with some platelets losing TMRM fluorescence by 60 minutes. AT-101-induced loss of TMRM 
fluorescence in some platelets within 10 minutes. As with AnV binding, the extent of sabutoclax-
induced loss of TMRM fluorescence was variable between experiments, but largely occurred after 90 
minutes.  
These data suggest that ABT-263 acts in a similar manner to ABT-737, as expected. Since AT-101, 
HA14-1 and sabtuoclax are structurally distinct to ABT-737 yet cause PS exposure and release of PS-
exposing EVs, we chose to investigate these putative BH3 mimetics in more detail.  
 
The putative BH3 mimetics show differential dependence on caspase and calpain activity 
ABT-737-induced PS exposure requires caspase activity.1,2 Consistent with this, Q-VD-OPh (50 µM), a 
pan-caspase inhibitor, abolished AnV binding to platelets treated with ABT-737 or ABT-263 (Fig. 3A). 
In contrast, Q-VD-OPh did not affect AnV+ binding in response to HA14-1, AT-101 or sabutoclax. 
QVD-Oph abolished AnV+ EV release in response to ABT-737, and partially inhibited AnV+ EV release 
in response to HA14-1 and sabutoclax (Fig. 3B).  
Calpeptin, a calpain inhibitor, had little effect on ABT-737, AT-101 or sabutoclax-induced AnV+ 
binding. In contrast, HA14-1-induced AnV+ binding was almost completely inhibited (Fig. 3A). As 
previously reported, calpeptin inhibited ABT-737-induced AnV+ EV release.4 AT-101 and HA14-1 
triggered AnV+ EV release to a similar level as ABT-737  and was also inhibited by calpeptinIn 
contrast, AnV+ EV release was lower in response to sabutoclax, and this was not significantly affected 
by calpeptin (Fi.g 3B).  
 
The putative BH3 mimetics show differential inhibition by R5421 
The putative scramblase inhibitor, R5421,19 also showed differential inhibition. R5421 abolished 
AnV+ binding in response to ABT-737, ABT-263 and HA14-1, with no inhibition of AnV+ binding in 
response to AT-101 or sabutoclax (Fig. 3A). R5421 prevented AnV+ EV release in response to all 
putative BH3 mimetics (Fig. 3B).  
 
The BH3 mimetics show different effects on [Ca2+]cyt  
ABT-737 treatment leads to disruption of platelet Ca2+ homeostasis.1,20 To compare the effect of the 
different BH3 mimetics on platelet [Ca2+]cyt, platelets were loaded with the Ca2+-sensitive fluorescent 
dye, Cal-520. Fluorescence was recorded every minute for 3 hours following addition of the BH3 
mimetic and normalised to the fluorescence of platelets at t=0 treated with DMSO (as the vehicle) 
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instead of the drug (F/FD). An expanded view of the first 30 minutes is in SFig. 1. ABT-737 (10 M) 
increased F/FD within 5 minutes to 1.31 ± 0.09 (Fig. 4A-B; see SFig. 1). This was prevented by pre-
treatment with Q-VD-OPh or calpeptin, or by absence of extracellular CaCl2 (100 M EGTA added). 
The small increase in fluorescence remained stable for around 60 minutes before it began to steadily 
increase, reaching F/FD = 3.62 ± 0.13 (n = 5) by 180 minutes. This was also inhibited by Q-VD-OPh. 
Calpeptin and absence of extracellular CaCl2 both partially inhibited this increased fluorescence (Fig. 
4C).  
AT-101 and sabutoclax also increased Cal-520 fluorescence. Both showed a small initial increase 
followed by a slow but larger increase in F/FD (Fig. 4A). The extent of the later increase was always 
lower than that induced by ABT-737 in matched samples. Addition of EGTA completely abolished the 
late increase induced by either AT-101 or sabutoclax, whereas Q-VD-OPh had little effect. 
Interestingly, calpeptin enhanced the late increase in [Ca2+]cyt. These data suggest that the effects of 
AT-101 and sabutoclax on [Ca2+]cyt are mechanistically different to the effects of ABT-737.  
HA14-1, in contrast, rapidly increased F/FD to 1.96 ± 0.07 at 5 minutes. This was not significantly 
affected by removal of extracellular CaCl2 and addition of EGTA (F/FD = 2.11 ± 0.09 at 1 minute; n = 5; 
p > 0.05). F/FD declined from this rapid peak over the course of 2-3 hours. Q-VD-OPh had no effect 
on this pattern of [Ca2+]cyt signalling. Calpeptin had a small effect on the peak magnitude of the signal 
(Fig. 4). These data suggest that the effects of HA14-1 are also different to any of the other drugs 
tested.  
 
The BH3 mimetics differentially affect plasma membrane integrity 
To assess loss of plasma membrane integrity, platelets were loaded with the fluorescent dye, 
calcein. Prolonged treatment with ABT-737 leads to loss of calcein fluorescence from some platelets 
suggesting progression from apoptosis into secondary necrosis.4 We readily repeated this 
observation, and the finding that calcein loss is prevented by inhibition of caspase or calpain activity 
(Fig. 5). Few platelets lost calcein fluorescence in response to AT-101 or HA14-1 treatment (5.1 ± 3.1 
% and 2.8 ± 1.2 %, respectively), despite inducing PS exposure in a similar percentage of platelets to 
ABT-737 (Fig. 1). Sabutoclax, by contrast, induced calcein loss in 41.3 ± 14.6 % (n = 5) of platelets; on 
average, this was unaffected by calpeptin (45.8 ± 16.9 %; n = 5; p > 0.05) but inhibited by QVD-Oph 
(4.6 ± 1.0 %; n = 5; p < 0.001) and the absence of extracellular CaCl2 (0.5 ± 0.2 %; n = 5; p < 0.001). 
However, it was also notable that the effect of sabutoclax was highly variable in the 5 independent 
experiments, making is more difficult to draw firm conclusions regarding sabutoclax (range: 2.3 – 
72.2 %; for comparison, the range of calcein negative platelets ABT-737 in experiments paired with 
those with sabutoclax was 23.6 – 35.2 %).  
 
Discussion 
Cancer cells often avoid apoptosis by upregulating anti-apoptotic Bcl-2 family proteins, including Bcl-
2 and Bcl-xL. These anti-apoptotic proteins are antagonised by pro-apoptotic BH3-only proteins. This 
has made small molecule BH3 mimetics an attractive approach to trigger apoptosis in these cancer 
cells.21,22 However, Bcl-xL is also an essential regulator of platelet lifespan.3 ABT-263 and ABT-737, 
which inhibit Bcl-xL, trigger the intrinsic apoptosis pathway in platelets, leading to PS exposure in 
vitro and thrombocytopenia in vivo.1,2    
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ABT-737, -263 and -199 are not the only molecules reported to act as BH3 mimetics. Several pro-
apoptotic drugs that have been reported to be BH3 mimetics are molecules related to gossypol, a 
natural phenol found in cotton plants, and which may underlie the toxicity of cotton seed.23 These 
include AT-101, the (-) enantiomer of gossypol, sabutoclax, and TW-37. In addition, HA14-1 is a 
structurally distinct small molecule that also reportedly acts as a BH3 mimetic. We are not aware of 
any studies investigating whether these drugs cause thrombocytopenia in patients or animal models 
in vivo.  
As expected, ABT-737 and ABT-263 triggered PS exposure in a concentration-dependent manner, 
whereas ABT-199 had no effect. TW-37 also had little effect on platelets. TW-37 was developed by 
structure-based design from AT-101 to be more selective for Bcl-2 over Bcl-xL,8 in an analogous 
manner to the later development of ABT-199 from ABT-263. The lack of effect of TW-37 and ABT-
199 is consistent with the lack of role of Bcl-2 in mouse platelet survival.24 AT-101, HA14-1 and 
sabutoclax also triggered PS exposure and release of PS-exposing EVs. Since AT-101, HA14-1 and 
sabtuoclax are structurally distinct to ABT-737 yet cause PS exposure and release of PS-exposing EVs, 
we chose to investigate these putative BH3 mimetics in more detail. 
The pharmacology of platelet PS exposure indicates that these molecules are acting through 
different mechanisms. PS exposure triggered by ABT-737 was dependent on caspases, as it was 
abolished by a pan-caspase inhibitor. In contrast, this inhibitor did not affect PS exposure triggered 
by AT-101, HA14-1 or sabutoclax. Caspase-dependency is not per se a sufficient indictor of 
apoptosis.25 However, the difference between ABT-737 – whose action has been shown to be 
apoptosis through its dependence on Bak/Bax – and these other putative BH3 mimetics suggests 
that the latter act through a non-apoptotic mechanism.  
The putative scramblase inhibitor, R5421, inhibited platelet PS exposure in response to ABT-737, 
ABT-263 and HA14-1, but had little effect on PS exposure in response to AT101 or sabutoclax. The 
specificity of R5421 is unclear. Previous studies demonstrate that although the Ca2+dependent 
scramblase, TMEM16F, partially contributes to ABT-737-induced PS exposure, some PS exposure is 
TMEM16F-independent. R5421 is likely to inhibit targets in addition to TMEM16F (Sarah Millington-
Burgess, personal communication; see OC27.4 in ref. 26). However, whatever its targets, the 
differential inhibition of platelet AnV+ binding by R5421 further indicates that there are important 
differences in the mechanisms of action of these putative BH3 mimetics.  
The pharmacology of PS-exposing EV release is also different between the putative BH3 mimetics. 
Interestingly, it is also different from the pharmacology of platelet PS exposure. Caspase inhibition 
partially inhibited release of PS-exposing EVs in response to AT-101 and HA14-1 despite not affecting 
platelet PS exposure. PS-exposing EV release in response to AT-101 and sabutoclax was inhibited by 
R5421 despite no effect on platelet PS exposure. These observations show that inhibition of PS-
exposing EV release by R54421 is not simply a consequence of inhibition of PS exposure, further 
suggesting its lack of specificity. Moreover, the different sensitivity to inhibition compared to ABT-
737 further shows that these putative BH3 mimetics have different mechanisms of action.  
ABT-737 treatment disrupted intracellular Ca2+ homeostasis in a biphasic manner. There was a small 
initial increase in [Ca2+]cyt followed by a later and larger increase. The small initial increase may be 
related to the small, transient increase that we have previously reported.20 The later, larger, 
sustained increase in [Ca2+]cyt was largely dependent on Ca2+ entry from the extracellular medium, as 
it was prevented by chelating extracellular Ca2+. A sustained increase in [Ca2+]i has been previously 
reported.27 There also appears to be a component of Ca2+ release from intracellular Ca2+stores, 
consistent with the depletion of these stores that has been previously reported. 1,20 Ca2+ entry may 
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occur through Ca2+ channels, though some may also be passive Ca2+ entry as the platelets gradually 
lose plasma membrane integrity. This could account for the inhibitory effect of calpeptin, since 
calpeptin also inhibited the loss of plasma membrane integrity during secondary necrosis.4 Whatever 
the precise mechanisms by which intracellular Ca2+ homeostasis is lost, caspase activation is a key 
step. Caspase inhibition prevented the initial and late increases in [Ca2+]cyt.  
The differences between the various BH3 mimetics are clearly seen in the different patterns of 
[Ca2+]cyt that they induce, and the different effects of protease inhibitors. The [Ca2+]cyt signal in 
response to AT-101 or sabutoclax was unaffected by Q-VD-OPh, in a similar manner to PS exposure. 
Interestingly, calpeptin enhanced the [Ca2+]cyt signal induced by these two BH3 mimetics. Although 
much more work is required to understand how this may occur, it clearly shows that the 
mechanisms that underlie [Ca2+]cyt signalling in response to these drugs is different to the 
mechanisms triggered by ABT-737.  
The [Ca2+]cyt signals triggered by HA14-1 are different again. Here, they appear similar to those 
triggered by receptor activation, with a rapid initial peak followed by a slow decline back to baseline. 
This signal was largely unaffected by either Q-VD-OPh or by calpeptin. It was also unaffected by 
chelation of extracellular Ca2+, suggesting that it involves rapid, transient release from intracellular 
Ca2+ stores. In future studies it would be interesting to determine whether HA14-1 acts directly on 
the intracellular Ca2+ stores or acts as a receptor agonist in an off-target manner.  
We have previously shown that prolonged treatment with ABT-737 in vitro leads to secondary 
necrosis, shown by loss of plasma membrane integrity.4 We did not observe a similar response with 
HA14-1 or AT-101 at 3 hours. Whether this reflects a difference in mechanism of action of these 
drugs, or simply a slower action than ABT-737, is not possible to determine from these data. 
Interestingly, the effect of sabutoclax was highly variable with a large range in the percentage of 
platelets that lost plasma membrane integrity. The reasons for this are unclear but suggest that any 
in vivo effect of sabutoclax could be similarly variable between individuals.  
ABT-737 is, to our knowledge, the only member of this drug class whose action has been shown to 
depend on Bak/Bax in mouse platelets,3 making it the only drug that can be clearly classified as 
acting as BH3 mimetics in platelets,28,29 although it is likely that ABT-263 acts in a similar manner. 
Since there are clear differences between the action of ABT-737 and the other putative BH3 
mimetics investigated here, AT-101, HA14-1 and sabutoclax cannot be considered as acting as BH3 
mimetics in platelets. Furthermore, the platelet death caused by these drugs is likely to be distinct 
from apoptosis. Studies in other cells have shown that these molecules cause apoptosis-
independent cell death. Sabutoclax induces mitochondrial fragmentation.30 Sabutoclax, gossypol and 
apogossypol-induced cell death is independent of Bak/Bax and may also involve mitochondrial 
damage.28,31 Although HA14-1-induced cell death is Bax-dependent in some models, it may also 
directly affect mitochondria and the endoplasmic reticulum.32 Although our study also argues against 
the use of these drugs as BH3 mimetics in platelets, it does also hint at the possibility of other cell 
death pathways in platelets. For example, platelet death through reactive oxygen species has been 
implicated for several chemotherapeutic drugs.33–37 Drug-induced non-apoptotic platelet death may 
be an important factor in chemotherapy-related thrombosis or thrombocytopenia and should be 
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Figure Legends 
Figure 1: Effect of putative BH3 mimetics on PS exposure and PS-exposing EV release. (A) Washed 
human platelets were stimulated with the indicated drugs (10 µM, 3 hours), or the vehicle (DMSO, 
0.1 %) after which samples were stained with anti-CD41-PerCP-Cy7, and annexin V (AnV)-FITC to 
detect PS exposure. PerCP-Cy7 fluorescence was used to trigger acquisition of CD41+ events. The 
panels show density plots of events from low density (blue) to high density (red) of forward scatter 
(FSC) and FITC fluorescence. The vertical line separating left and right was defined by the FSC-A of 1 
µm silica beads. The density plots are representative of data from 5 different donors. (B-C) The 
percentage of AnV +ve platelets (CD41+, > 1 m) or AnV +ve EVs (CD41+, < 1 m) following 
treatment with the indicated concentration of each drug (3 hours). Data are mean + s.e.m. (n = 5; * p 
< 0.05; *** p < 0.001 compared to DMSO).  
 
Figure 2: Timecourse of PS exposure and loss of mitochondrial membrane potential. (A) TMRM-
loaded platelets were treated with the indicated drugs (10 M). The percentage of AnV +ve platelets 
is shown in (A) and the percentage of TMRM +ve platelets is shown in (B). Data are mean + s.e.m. (n 




Figure 3: Pharmacology of PS exposure and PS-exposing EV release. Platelets were treated with Q-
VD-OPh (50 µM), calpeptin (140 µM), R5421 (50 µM) or DMSO (0.1 %; vehicle control) for 30 
minutes prior to stimulation. CaCl2 (2 mM) was added where indicated. Platelets were then 
stimulated with the indicated putative BH3 mimetics (10 µM, 3 hours). The percentage of AnV +ve 
platelets (A) or number of AnV +ve EVs (B) was determined as in Figure 1. Data are mean + s.e.m. (n 
= 5; * p < 0.05; ** p < 0.01; *** p < 0.001 compared to platelets treated with DMSO prior to 
stimulation with the indicated BH3 mimetic, with 2mM CaCl2).  
 
Figure 4: Effect of putative BH3 mimetics on cytosolic Ca2+ concentration. Cal-520-loaded platelets 
were treated with Q-VD-OPh, calpeptin, or DMSO as control prior to stimulation with the indicated 
drugs. 2mM CaCl2 was added (expect where EGTA, 100 µM was added instead). Fluorescence was 
recorded every minute for 3 hours following addition of the BH3 mimetic and normalised to the 
fluorescence of platelets at t=0 treated with DMSO instead of the putative BH3 mimetic (F/FD). 
Traces show mean ± s.e.m. (n = 5). The mean F/FD at 5 min and 180 min is shown in (B) and (C), 
respectively. Data are mean + s.e.m. (n = 5; * p < 0.05; ** p < 0.01; *** p < 0.001 compared to 
DMSO-treated with 2mM CaCl2). 
 
Figure 5: Effect of putative BH3 mimetics on plasma membrane integrity. Calcein-loaded platelets 
were treated with Q-VD-OPh, calpeptin, or DMSO as control prior to stimulation with the indicated 
drugs. 2mM CaCl2 was added except where indicated (these 0 mM CaCl2 samples also had DMSO). 
The percentage of calcein negative (-ve) platelets was determined by flow cytometry. Individual data 
(n = 5) are shown to emphasize the variability in response to sabutoclax (see main text). The 
horizontal bar indicates the mean. ** p < 0.01; *** p < 0.001 compared to DMSO-treated with 2mM 
CaCl2. 
 
Table 1: Summary of pharmacology of putative BH3 mimetics. The effect of QVD-Oph (Q), calpeptin 
(C), R5421 (R) or lack of extracellular CaCl2 (No Ca) on the responses measured is shown. ‘x’ indicates 
that the treatment inhibited the response; ‘+’ indicates that the treatment increased the response; ‘-
‘ indicates that the putative BH3 mimetic did not cause that response.   
  PS exposure PS-exposing EV 
release 






Q C R No 
Ca 
Q C R No 
Ca 
Q C No 
Ca 
Q C No 
Ca 
ABT-737  x  x x x x x x x x x x x x 
AT-101     x x x x x  + x - - - 
HA14-1   x x x x x x x  x  - - - 
Sabutoclax     x   x x  + x x  x 
 
 
Supplementary Figure 1: Expanded portion of Cal-520 signals. These are the initial 30 minutes of 
the mean traces shown in Fig. 4. Only the mean is shown for clarity. The vertical dotted line is the 5-
minute point quantified in Fig. 4B.  
